Please login to the form below

Not currently logged in


This page shows the latest patisiran news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn

Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn

Elsewhere in the therapy area is Alnylam’s Onpattro (patisiran), which received approval in hereditary ATTR amyloidosis (hATTR) in 2018.

Latest news

More from news
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
How to embrace behavioural science principles in healthcare MR...